{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-013597","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.828214+00:00","generated_at":"2026-06-15T06:09:09.303081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AcelRx Q1 net loss $8.2M; DSUVIA divestiture closed, Niyad EUA submitted","bullets":["Net loss $8.2M ($0.75/share) vs $8.7M loss in Q1 2022; cash $13.4M at March 31, 2023.","DSUVIA divestiture to Alora closed April 3; 15% royalty on commercial sales, 75% on DoD, up to $116.5M milestones.","EUA request for Niyad (nafamostat mesylate) submitted to FDA April 27; registrational study expected H2 2023.","Combined R&D and SG&A expenses $5.3M, up from $4.9M, driven by legal and Niyad costs.","Recognized $7.0M impairment on net assets held for sale from DSUVIA discontinued operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-013597","json":"https://secwatch.observer/filing/0001437749-23-013597.json","markdown":"https://secwatch.observer/filing/0001437749-23-013597.md","text":"https://secwatch.observer/filing/0001437749-23-013597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923013597/0001437749-23-013597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923013597/acrx20230509_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:09:09.303081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a0871e234cd61a76828c71a00d5c227faa75523","claim":"TALPHERA, INC. reported the first quarter of 2023 results: net income $8.2 million, EPS $0.75 per basic and diluted share.","evidence_excerpt":"Net loss attributable to common shareholders for the first quarter of 2023 was $8.2 million, or $0.75 per basic and diluted share, compared to a net loss of $8.7 million, or $1.19 per basic and diluted share, for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427925/000143774923013597/0001437749-23-013597-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Net income","value":"$8.2 million"},{"label":"EPS","value":"$0.75 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}